COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis. (4th July 2022)

• Record Type: Journal Article
• Authors: Ferrand, Nawfel; Accorinti, Massimo; Agarwal, Mamta; Spartalis, Christoph; Manni, Priscilla; Stuebiger, Nicole; Zierhut, Manfred
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 5(2022)
• Page Start: 1265
• Page End: 1273
• Publication Date: 2022-07-04
• Subjects: Adverse events -- COVID-19 vaccination -- side effects -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2022.2058964
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: To study the epidemiological and clinical features of uveitis post-COVID-19 vaccination. Patients and Methods: Retrospective chart review of patients presenting with uveitis after COVID-19 vaccination in tertiary uveitis services. Results: In total, 25 patients, 76% females, mean age 43.2 years, were included. Uveitis occurred after Pfizer, Moderna, Astra-Zeneca and Covaxin vaccination. Anterior uveitis was the most frequent type of uveitis (56%). History of uveitis was found in 19 cases (76%), among whom 90.9% of the tested patients developed anti-Sars-CoV-2 spike antibodies after vaccination. In a mean follow-up of 5 months, one-line decrease in visual acuity was found in 12% of patients. During post-vaccine uveitis, 15.8% of cases needed an increase in their systemic therapy. According to Naranjo score, new-onset uveitis had a higher probability of being associated with vaccination (p < .01). Conclusion: COVID-19 vaccination can cause uveitis but has no significant impact on the visual prognosis after resolution.